MYGN Myriad Genetics Inc.

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Correction: Time of BofA Conference

SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences:

  • The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.
  • Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025.

Live and archived webcasts of all presentations can be viewed at .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .

Investor Contact 

Matt Scalo 

(801) 584-3532 

 

Media Contact 

Kate Schraml

(224) 875-4493

  



EN
14/05/2025

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healt...

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Liv...

20h / 35m 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Announces RiskScore Study Published in JCO Precision O...

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integ...

May 7, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates ...

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, ben...

May 6, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Concerns about Mental Health Medication Side Effects Remain a Barrier ...

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor More than half say genetic testing for mental health medications could reduce concerns SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medicatio...

April 30, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Release First Quarter 2025 Financial Results on May...

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 Management will participate in two upcoming investor healthcare conferences SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance ...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch